Nanobiotix Updates Voting Rights and Shares Capital as of May 2025

An update from Nanobiotix ( (NBTX) ) is now available.

On June 10, 2025, Nanobiotix announced its voting rights and shares capital update, reporting 47,426,851 shares outstanding as of May 31, 2025, with 49,529,244 theoretical voting rights and 49,507,126 exercisable voting rights. This update is crucial for stakeholders as it informs them about the company’s current shareholding structure and voting power, which can impact shareholder decisions and company governance.

The most recent analyst rating on (NBTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.

Spark’s Take on NBTX Stock

According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.

Nanobiotix’s stock score is driven by severe financial challenges, offset partially by strong technical indicators and strategic partnerships. While the company faces significant risks due to its negative financial performance, the potential from its JNJ collaboration and technical momentum offer some upside potential.

To see Spark’s full report on NBTX stock, click here.

More about Nanobiotix

Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, focused on developing disruptive, physics-based therapeutic approaches to improve treatment outcomes for patients. Founded in 2003, the company is listed on Euronext Paris and the Nasdaq Global Select Market, and holds over 25 patent families related to nanotechnology platforms in oncology, bioavailability, biodistribution, and central nervous system disorders.

Average Trading Volume: 11,273

Technical Sentiment Signal: Hold

Current Market Cap: $223.1M

Find detailed analytics on NBTX stock on TipRanks’ Stock Analysis page.